Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Other Non-Current Liabilities: 2020-2022

Historic Other Non-Current Liabilities for Atea Pharmaceuticals (AVIR) over the last 2 years, with Sep 2022 value amounting to $5.2 million.

  • Atea Pharmaceuticals' Other Non-Current Liabilities was N/A to $5.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $5.2 million, marking a year-over-year change of. This contributed to the annual value of $5.9 million for FY2021, which is 16377.78% up from last year.
  • Per Atea Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $5.2 million for Q3 2022, which was down 13.95% from $6.0 million recorded in Q2 2022.
  • Atea Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $6.0 million for Q2 2022, and its period low was $29,000 during Q2 2021.
  • Its 3-year average for Other Non-Current Liabilities is $2.9 million, with a median of $2.6 million in 2021.
  • Data for Atea Pharmaceuticals' Other Non-Current Liabilities shows a peak YoY spiked of 20,617.24% (in 2022) over the last 5 years.
  • Over the past 3 years, Atea Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $36,000 in 2020, then surged by 16,377.78% to $5.9 million in 2021, then spiked by 20,617.24% to $5.2 million in 2022.
  • Its last three reported values are $5.2 million in Q3 2022, $6.0 million for Q2 2022, and $5.9 million during Q1 2022.